| Tetraphase Pharmaceuticals is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize tetracyclines for serious conditions, including bacterial infections caused by multidrug-resistant (MDR) bacteria. Co.'s product, Xerava (eravacycline), is an intravenous, antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections. In addition to Xerava, Co. has also developed other fluorocycline antibiotic compounds, TP-6076 and TP-271, and TP-2846, a tetracycline for the treatment of acute myeloid leukemia. We show 29 historical shares outstanding datapoints in our TTPH shares outstanding history coverage, used to compute TTPH market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TTPH market cap history over the course of time is important for investors
interested in comparing TTPH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TTPH versus a peer is one thing; comparing
TTPH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TTPH can fluctuate over the course of history.
With this page we aim to empower investors researching TTPH by allowing them to research the TTPH market cap history.